Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
Abstract
(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
- Inventors:
- Issue Date:
- Research Org.:
- Brookhaven National Laboratory (BNL), Upton, NY (United States)
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 1171656
- Patent Number(s):
- 8969413
- Application Number:
- 13/581,187
- Assignee:
- Catalyst Pharmaceutical Partners (Coral Gables, FL)
- Patent Classifications (CPCs):
-
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- DOE Contract Number:
- AC02-98CH10886
- Resource Type:
- Patent
- Resource Relation:
- Patent File Date: 2011 Feb 25
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
Citation Formats
Silverman, Richard B, Dewey, Stephen L, and Miller, Steven. Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid. United States: N. p., 2015.
Web.
Silverman, Richard B, Dewey, Stephen L, & Miller, Steven. Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid. United States.
Silverman, Richard B, Dewey, Stephen L, and Miller, Steven. Tue .
"Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid". United States. https://www.osti.gov/servlets/purl/1171656.
@article{osti_1171656,
title = {Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid},
author = {Silverman, Richard B and Dewey, Stephen L and Miller, Steven},
abstractNote = {(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2015},
month = {3}
}
Works referenced in this record:
Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
patent, October 2002
- Dewey, Stephen L.; Brodie, Jonathan D.; Ashby, Jr., Charles R.
- US Patent Document 6,462,084
Compounds and related methods for inhibition of &ggr;-aminobutyric acid aminotransferase
patent, September 2004
- Silverman, Richard B.; Pan, Yue
- US Patent Document 6,794,413
Treatment of addiction and addiction-related behavior using a composition of topiramate
patent, June 2005
- Dewey, Stephen L.; Brodie, Jonathan D.; Ashby, Jr., Charles R.
- US Patent Document 6,906,099
Compounds and related methods for inhibition of gamma-aminobutyric acid aminotransferase
patent, June 2008
- Silverman, Richard B.; Pan, Yue
- US Patent Document 7,381,748